5月23日 - ** 医疗设备制造商Delcath Systems DCTH.O股价上涨2%，报16.43美元
** H.C. Wainwright将DCTH的预测价格从24美元上调至29美元。
** DCTH 打算签订医疗补助国家药品回扣$(NDRA)$ 协议，"这是审慎之举，因为这不仅有助于获得更大的患者基础，还有助于实现可持续增长" - Wainwright
** 通过加入 NDRA，DCTH 的 Hepzato 套件将提供给所有医疗补助计划和医疗保险优势计划，从而大大增加其使用机会
** 公司的 Hepzato 套件是一种治疗癌症的药物-器械组合产品
** DCTH 已开始加入 NDRA，预计将于 2025 年第三季度生效。
** 截至上次收盘，该公司股价年累计涨幅超过 34
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.